Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Capecitabine × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 17 Stomach Neoplasms 11 Adenocarcinoma Of Esophagus 7 Neoplasm Metastasis 6 Rectal Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Esophageal Neoplasms 5 Colorectal Neoplasms 5 Triple Negative Breast Neoplasms 4 Colonic Neoplasms 3 Adenocarcinoma 3 Pathologic Complete Response 2 Neoplasms 2 Nasopharyngeal Carcinoma 2 Gallbladder Neoplasms 2 Cholangiocarcinoma 2 Anus Neoplasms 2 Somatostatinoma 1 Resectable Colon Cancer 1 Recurrence 1 Pancreatic Intraductal Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasm, Residual 1 Meningeal Neoplasms 1 Locally Advanced Rectal Cancer With Liver Metastases 1 Locally Advanced Rectal Cancer 1 Klatskin Tumor 1 Insulinoma 1 HIV Infections 1 HER2-positive Gastric Cancer 1

Interventions

pasireotide 1 E-7386 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡